Every state, kept current
The Rates plan
$29/mo7-day free trialThis page shows one representative rate per state for Q5167. Full schedules include every locality, modifier, and age-band variant.
- Every code on all 51 published schedules
- Full-schedule CSV export and state network lists
- Email alerts when a state changes its rates
$29/mo after the trial. Cancel anytime.
Publishing states
15
Median % of Medicare
--
Rate range
$2.15 - $9.79
Q5167 rates in every publishing state
| State | Medicaid rate | % of Medicare | Prior auth | Vintage |
|---|---|---|---|---|
| Arkansas | $6.08 | -- | -- | 2026 |
| Arizona | $2.99 | -- | -- | 2026 |
| California | $9.79 | -- | -- | 2026 |
| Illinois | $6.20 | -- | -- | 2026 |
| Kansas | $4.00 | -- | -- | 2026 |
| Michigan | $2.15 | -- | -- | 2026 |
| Minnesota | $5.33 | -- | Required | 2026 |
| Mississippi | $4.12 | -- | -- | 2026 |
| Montana | $4.12 | -- | -- | 2026 |
| Nebraska | $5.69 | -- | -- | 2026 |
| New Hampshire | $4.00 | -- | Not required | 2026 |
| Oklahoma | $4.00 | -- | -- | 2026 |
| Utah | $4.00* | -- | Required | 2026 |
| Washington | $4.00 | -- | -- | 2026 |
| Wisconsin | $6.67 | -- | -- | 2026 |
Published Medicaid fee-for-service schedule amounts, not a coverage or eligibility guarantee. Managed-care plan rates can differ. Where no prior-authorization flag is shown, the state does not publish one. Rows marked * are representative published variants or methodology-derived rates. "--" in the prior-auth column means the state publishes no PA flag.
Related state-specific services codes
- C1716 - Brachytherapy source, non-stranded, gold-198, per source
- C1717 - Brachytherapy source, non-stranded, high dose rate iridium-192, per source
- C1719 - Brachytherapy source, non-stranded, non-high dose rate iridium-192, per source
- C2616 - Brachytherapy source, non-stranded, yttrium-90, per source
- C2634 - Brachytherapy source, non-stranded, high activity, iodine-125, greater than 1.01 mci (nist), per source
- C2635 - Brachytherapy source, non-stranded, high activity, palladium-103, greater than 2.2 mci (nist), per source
- C2636 - Brachytherapy linear source, non-stranded, palladium-103, per 1 mm
- C2638 - Brachytherapy source, stranded, iodine-125, per source
All 56 codes from Q5098 to Q5167 or every state-specific services code by number.
Frequently asked questions
How much does Medicaid pay for Q5167?
15 state Medicaid programs publish a fee-for-service rate for Q5167 (injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg), ranging from $2.15 in Michigan to $9.79 in California. The full table on this page lists every publishing state's current rate.
Which state pays the most for Q5167?
California publishes the highest Medicaid rate for Q5167 at $9.79. Michigan publishes the lowest at $2.15.
Does Q5167 require prior authorization under Medicaid?
2 of the 15 publishing states flag Q5167 as requiring prior authorization (always or conditionally) on their fee schedules. States without a flag publish no PA indicator for this code - that means "not published", not "no PA required".